KRISTALLINE FORMEN
European patent · EP3515924 · In force
Register entry
- Publication number
- EP3515924
- Application number
- EP17771436
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Sep 21, 2017
- Published
- Jul 31, 2019
- Granted
- Dec 15, 2021
- Protection ends at the latest
- Sep 20, 2037
- Next annual fee due
- Sep 30, 2027
- IPC classes
- C07F 9/6558 (2006.01)A61K 31/675 (2006.01)A61P 9/00 (2006.01)
- Priority
- WO PCT/EP2016/072562 22.09.2016
- PCT application
- PCT/EP2017/073858 21.09.2017
- PCT publication
- WO2018/055016 29.03.2018
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Oct 1, 2026
Next annual fee due on
- Next annual fee due on
- 30.09.2026 → 30.09.2027
Published in Swissreg on 01.10.2026
- Oct 1, 2025
Next annual fee due on
- Next annual fee due on
- 30.09.2025 → 30.09.2026
Published in Swissreg on 01.10.2025
- Sep 19, 2025
Transferred
- Owner
- Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil → Viatris Asia Pacific Pte. Ltd., 2 Shenton Way, #18-01, SGX Centre 1, Singapore 068804, Singapore
- Representative
- BOVARD AG, Optingenstrasse 16, 3013 Bern
Published in Swissreg on 19.09.2025
- Oct 3, 2024
Change
Published in Swissreg on 03.10.2024
- Oct 1, 2023
Change
Published in Swissreg on 01.10.2023
- Oct 26, 2022
Change
Published in Swissreg on 26.10.2022
- Oct 1, 2022
Change
Published in Swissreg on 01.10.2022
- Dec 15, 2021
Granted
Published in Swissreg on 15.12.2021
Parties
Inventor
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.